Quantcast

DaVita Clinical Research to Present Results on Safety of Biosimilars, Treating Depression, Burden of Diabetic Foot Ulcers

April 21, 2014

LAS VEGAS, April 21, 2014 /PRNewswire-USNewswire/ — DaVita Clinical Research (DCR), a specialty contract research organization with services spanning the full spectrum of drug and device development, today announced that company representatives will present four abstracts at National Kidney Foundation’s (NKF) 2014 Spring Clinical Meeting, which takes place April 22-26, 2014 in Las Vegas.

http://photos.prnewswire.com/prnvar/20140212/DC63568LOGO

The NKF Spring Clinical Meeting is a platform for the nation’s leading kidney care providers to learn about new developments related to all aspects of nephrology and is expected to attract nearly 3,000 health care professionals in 2014.

Representatives from DaVita Kidney Care, a division of DaVita HealthCare Partners Inc., and DCR will present results from both DaVita’s innovative clinical quality initiatives and clinical research originating from DCR and its research partners.

“Our goal at DaVita is to move up the clinical pyramid and improve mortality, morbidity and patient quality of life. Innovating through clinical quality initiatives is one important way we do that,” said Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president of clinical innovation and public policy at DaVita. “Translational research and meaningful quality initiatives, as are included among these abstracts, are essential for improving health care. These findings further solidify DaVita’s commitment to investing in improved patient outcomes.”

DaVita will share the results from the following clinical quality initiatives during the poster session on Wednesday, April 23, from 6:00 to 7:30 p.m.:

    --  "Treating depression in the dialysis setting: validating Symptom
        Targeted Intervention," presented by Shaun Boyd, L.S.W., poster 155
    --  "Root Causes of Lack of Adherence to Mineral Bone Disease (MBD)
        Medication in ESRD Patients," presented by Maureen McKinley, L.S.W.,
        poster 408

In addition, the findings from the following health outcomes research studies will be presented during the poster session scheduled for April 23, from 6:00 p.m. to 7:30 p.m.:

    --  "Economic Impact of Ferric Citrate (FC) versus Standard of Care for
        Hemodialysis Patients," presented by Steven M. Brunelli, M.D., M.S.C.E.,
        poster 156
    --  "Disease Burden of Diabetic Foot Ulcers in End-Stage Renal Disease,"
        presented by Scott Sibbel, Ph.D., M.P.H., poster 221

DCR seeks to advance the future of medicine, the practice of medicine and to innovate through personalized medicine. DCR and DaVita share a dedication to improving the health and quality of life for kidney care patients.

DaVita, DaVita Clinical Research and DCR are trademarks or registered trademarks of DaVita Healthcare Partners Inc. All other trademarks are the property of their respective owners.

About DaVita Kidney Care

DaVita Kidney Care is a division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of dialysis services in the United States, DaVita Kidney Care treats patients with chronic kidney failure and end stage renal disease. DaVita Kidney Care strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of Dec. 31, 2013, DaVita Kidney Care operated or provided administrative services at 2,074 outpatient dialysis centers located in the United States serving approximately 163,000 patients. The company also operated 73 outpatient dialysis centers located in ten countries outside the United States. DaVita Kidney Care supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.

About DaVita Clinical Research

DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners Inc., uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment, and completion of clinical trials including retrospective and prospective pragmatic trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 150 client companies. DCR’s Biorepository, Early Clinical Research unit (Phase I-IIa) and Late Phase Clinical Research (Phase IIb through post-marketing) network of physicians and investigative sites, data research, Health Economics & Outcomes Research, Central Laboratory, and Medical Communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.

Logo – http://photos.prnewswire.com/prnh/20140212/DC63568LOGO

Contact Information

Media:

Bianca Violante

Office: (303) 876-6614

Mobile: (443) 417-6044

Bianca.Violante@DaVita.com

SOURCE DaVita Inc.


Source: PR Newswire



comments powered by Disqus